Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Abeona Therapeutics (ABEO) over the last 13 years, with Dec 2024 value amounting to -$68.4 million.

  • Abeona Therapeutics' Income towards Parent Company fell 17.47% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.1 million, marking a year-over-year increase of 4.84%. This contributed to the annual value of -$68.4 million for FY2024, which is 43.88% down from last year.
  • As of FY2024, Abeona Therapeutics' Income towards Parent Company stood at -$68.4 million, which was down 43.88% from -$47.6 million recorded in FY2023.
  • In the past 5 years, Abeona Therapeutics' Income towards Parent Company registered a high of -$47.6 million during FY2023, and its lowest value of -$93.4 million during FY2021.
  • Moreover, its 3-year median value for Income towards Parent Company was -$51.7 million (2022), whereas its average is -$55.9 million.
  • In the last 5 years, Abeona Therapeutics' Income towards Parent Company soared by 44.71% in 2022 and then slumped by 43.88% in 2024.
  • Abeona Therapeutics' Income towards Parent Company (Yearly) stood at -$84.2 million in 2020, then declined by 10.91% to -$93.4 million in 2021, then spiked by 44.71% to -$51.7 million in 2022, then rose by 7.93% to -$47.6 million in 2023, then plummeted by 43.88% to -$68.4 million in 2024.